1. Scrip
  2. >>Business
  3. >>Deals

Actavis builds antibiotic presence with $675m+ Durata deal

 
• By Eleanor Malone

Antibiotic developer Durata Therapeutics saw its share price rocket by up to 75% after Actavis announced a deal to acquire the Nasdaq-listed firm. Its shares rose from Friday's close of $13.88 to upwards of $24.30 during trading on Monday.

Antibiotic developer Durata Therapeutics saw its share price rocket by up to 75% after Actavis announced a deal to acquire the Nasdaq-listed firm. Its shares rose from Friday's close of $13.88 to upwards of $24.30 during trading on Monday.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

In Brief: Sanofi Gains €10bn From Opella Sale

 
• By Sushmita Panda

Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

Novartis Gains Further Renal Territory With Regulus Acquisition

 
• By Alaric DeArment

The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

More from Business